LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process

Stock News

Jan 07

LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1153150074"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153150074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153150074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153150074","market":"other","top_or_hot":-1,"title":"LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-07 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1153150074","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153150074","pubTimestamp":1767782761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药","BK1191":"制药"},"translate_title":"丽珠医药(01513)：莱康奇他单抗注射液纳入优先审评审批程序","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}